VNS Therapy System
LivaNova USA, Inc. · Decision date Oct 2, 2026
What did the FDA approve?
FDA supplement P970003/S254 records an approval for a change in the battery voltage offset used in the battery longevity calculation for the VNS Therapy System. The offset is to be applied over 15% of battery usage instead of the previous 7.5%.
The supplement is classified as a Real-Time Process for a change in design, components, specifications, or material. The applicant is LivaNova USA, Inc., and the device category is an implanted autonomic nerve stimulator for epilepsy. The decision statement does not describe clinical testing, safety outcomes, or effectiveness data.
FDA approval order statement
approval for change in the battery voltage offset in battery longevity calculation to be applied over 15% of battery usage instead of 7.5%.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Oct 2, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P970003/S254
- Regulatory pathway
- PMA supplement
- Applicant
- LivaNova USA, Inc.
- Product code
- LYJ
- Decision code
- APPR
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.
- Applicant
- LivaNova USA, Inc.
- Product code
- LYJ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P970003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P970003 · Original PMA
VNS THERAPY SYSTEM
P970003/S254 received
Application receipt date recorded by FDA.
P970003/S254 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VNS THERAPY SYSTEMP970003 | LivaNova USA, Inc. | PMA approval | Jul 16, 1997 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
LivaNova USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Cyberonics Blvd., Houston, TX, 77058
Sources and methodology
- Original FDA record: P970003/S254
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records